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Several known or putative glycosyltransferases are required for the synthesis of laminin-binding glycans on
alpha-dystroglycan (aDG), including POMT1, POMT2, POMGnT1, LARGE, Fukutin, FKRP, ISPD and GTDC2.
Mutations in these glycosyltransferase genes result in defective aDG glycosylation and reduced ligand bind-
ing by aDG causing a clinically heterogeneous group of congenital muscular dystrophies, commonly re-
ferred to as dystroglycanopathies. The most severe clinical form, Walker–Warburg syndrome (WWS), is
characterized by congenital muscular dystrophy and severe neurological and ophthalmological defects.
Here, we report two homozygous missense mutations in the b-1,3-N-acetylglucosaminyltransferase 1
(B3GNT1) gene in a family affected with WWS. Functional studies confirmed the pathogenicity of the muta-
tions. First, expression of wild-type but not mutant B3GNT1 in human prostate cancer (PC3) cells led to
increased levels of aDG glycosylation. Second, morpholino knockdown of the zebrafish b3gnt1 orthologue
caused characteristic muscular defects and reduced aDG glycosylation. These functional studies identify
an important role of B3GNT1 in the synthesis of the uncharacterized laminin-binding glycan of aDG and im-
plicate B3GNT1 as a novel causative gene for WWS.
INTRODUCTION
Dystroglycanopathies are caused by reduced glycosylation of
alpha-dystroglycan (aDG) (1,2). This group of muscular
dystrophy-dystroglycanopathy syndromes includes a range of
clinical phenotypes. Walker–Warburg syndrome (WWS;
MIM 236 670), muscle–eye–brain disease (MEB; MIM
253 280) and Fukuyama congenital muscular dystrophy
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(FCMD; MIM 253 800) represent the most severe end of the
clinical spectrum. These disorders cause muscular dystrophy
and severe eye and brain abnormalities resulting in early in-
fantile death (3). The mildest variant of the dystroglycanopa-
thies is adult-onset limb-girdle muscular dystrophy (LGMD;
MIM 607 155), associated with mutations in the fukutin-
related protein (FKRP) gene (4).
aDG and beta-dystroglycan (bDG) are central components
of the dystrophin–glycoprotein complex (DGC), which forms
a link between the cytoskeleton and the basal lamina. The per-
ipheral membrane aDG protein is connected to the cytoskel-
eton via non-covalent binding with the transmembrane bDG
protein that is linked to intracellular actin. The link with the
basal lamina is formed by the binding of aDG to several
tissue-specific extracellular matrix (ECM) proteins, including
laminin, agrin, perlecan, neurexin and pikachurin (5–11).
aDG is highly glycosylated with N-glycans, mucin type
O-glycans and O-mannose type glycans (12–14). aDG–
ligand binding requires specific glycosylation of aDG (6)
through O-linked mannosylation of serine or threonine resi-
dues. The proposed ligand-binding glycan occurs on a
phosphodiester-linked O-mannose residue (15).
Reduced aDG–ligand binding caused by hypoglycosylation
of aDG has been suggested to be the underlying cause for the
dystroglycanopathies (1,2). Mutations in POMT1, POMT2,
POMGNT1, LARGE, FKTN, FKRP, ISPD and GTDC2, encod-
ing known or putative glycosyltransferases, and a mutation in
the dystroglycan gene (DAG) itself give rise to dystroglycano-
pathies with specific O-glycosylation defects (4,16–23). Fur-
thermore, the phenotypes of patients with mutations in genes
involved in producing the sugar precursor dolichol-phosphate
mannose (DOLK, DPM3, DPM2 and likely DPM1) are asso-
ciated with dystroglycanopathies with combined N- and
O-linked glycosylation defects (24–26). The mannose group
of dolichol-phosphate mannose is used during the first step
of the O-mannosylation of aDG by an O-mannosyltransferase
complex that is encoded by POMT1 and POMT2 (27). Protein
O-linked-mannose b-1,2-N-acetylglucosaminyltransferase 1
(POMGnT1) is involved in the second step of the O-mannosy-
lation. This enzyme adds an N-acetylglucosamine residue to
the first mannose (18). The exact functions of the proteins
encoded by FKTN, FKRP, ISPD and GTDC2 are still
unknown. However, the protein products of these genes
might play a role in the glycosylation of the phosphorylated
O-mannose glycan (15). LARGE has been shown to act as a
bifunctional glycosyltransferase that transfers both xylose
and glucuronic acid. These glycan modifications allow aDG
to bind ECM ligands (28). Recently, a mutation was identified
in the DAG1 gene, which encodes the dystroglycan precursor
protein that is post-transcriptionally cleaved into aDG and
bDG (29). This mutation, identified in a patient with an
LGMD phenotype, interfered with post-translational modifica-
tions involving LARGE (30).
Mutation analysis of all known dystroglycanopathy genes
has revealed the underlying genetic aetiology in 50% of
individuals from our cohort of patients with a severe dystro-
glycanopathy phenotype, suggesting that more genes remain
to be discovered. The identification of new genes is important
to increase insights into the nature of the unknown ligand-
binding glycan. This study provides the first evidence that
mutations in b-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1)
can give rise to WWS.
RESULTS
Homozygosity mapping and B3GNT1 mutation analysis
To identify causative mutations for WWS, we previously per-
formed homozygosity mapping in 30 families with idiopathic
WWS using the Affymetrix GeneChip Human Mapping SNP
Array (21). Eight families showed homozygosity at 11q13,
containing the B3GNT1 gene, which was associated with
aDG glycosylation before in a cellular model of prostate
cancer (31). For this reason, we followed a candidate gene ap-
proach and focused on B3GNT1 in our cohort. In one of these
families (WWS-31), the homozygous region was delimited by
SNP_A-4215126 at 11q13.1 and SNP_A-2154685 at 11q13.3
(UCSC hg19 database, http://genome.ucsc.edu, last accessed
date on 30 January, 2013), representing a 5.24 Mb haplotype
that was shared among the three affected individuals but dif-
ferent from that in an unaffected sibling. In this family, we
detected two homozygous missense mutations in the coding
sequence of B3GNT1. No B3GNT1 mutations were detected
in any of the other seven families with homozygosity at
11q13.1, nor in any of the 47 additional families from our dys-
troglycanopathy cohort. Both mutations are absent in 5379
control samples from the NHLBI GO Exome Sequencing
Project (Exome Variant Server, http://evs.gs.washington.edu/
EVS, last accessed date on 30 January, 2013) and in 672
exomes of our in-house database.
B3GNT1 is a type II transmembrane protein and both muta-
tions are located in the conserved glycosyltransferase domain
(Glyco_transf_49, pfam13896; Fig. 1; Supplementary Mater-
ial, Fig. S1). The first mutation, c.1168A. G (M1), is pre-
dicted to lead to a substitution of asparagine by aspartic acid
(p.Asn390Asp), while the second mutation, c.1217C . T
(M2), replaces alanine by valine (p.Ala406Val). Screening
of all available family members showed co-segregation with
disease, with all affected members being homozygous and
all unaffected individuals being heterozygous for both the
mutations (Supplementary Material, Fig. S2).
Clinical report
The index family (WWS-31) without known consanguinity is
of East Indian descent with four siblings diagnosed with WWS
and three unaffected sibs (Fig. 1E) (clinical details are
described in the Materials and Methods section). Three preg-
nancies were terminated and one affected son died at 2
years of age. He presented with hydrocephalus, Dandy–
Walker malformation, retinal dysplasia, severe hypotonia
and seizures. His creatine kinase (CK) level was very high
(3180 units/l). The magnetic resonance imaging (MRI,
Fig. 2A–D) showed typical WWS characteristics such as ven-
tricular enlargement, diffuse widening of the gyri and disor-
ganization of the cortical sulci with areas of cobblestone
lissencephaly along the posterior aspects of the occipital
lobes and temporal lobes. Besides, the white matter, brain
stem and cerebellum were clearly affected. From one of the
fetuses, a muscle biopsy was taken. The skeletal muscle
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showed a lack of merosin and a-sarcoglycan expression. In
addition, aDG was not able to bind laminin as assessed by
laminin overlay in skeletal muscle homogenate (Fig. 2E).
Overexpression of wild-type and mutant B3GNT1
in human PC3 cells
To investigate the functional consequences of the mutations,
we first determined the subcellular localization of wild-type
and mutant B3GNT1. We used human prostate cancer (PC3)
cells with low levels of endogenous aDG glycosylation (31).
We transfected PC3 cells with enhanced green fluorescent
protein (EGFP)-tagged wild-type and mutant B3GNT1 con-
structs. Wild-type and single or double mutant fusion proteins
localized to the Golgi apparatus of transfected cells, as deter-
mined by co-localization with the Golgi marker Giantin
(GOLGB1, Fig. 3). These results show that the mutations do
not affect B3GNT1 subcellular localization.
To investigate the effect of wild-type and mutant forms of
B3GNT1 on aDG glycosylation, a flow cytometry assay was
performed using the IIH6 antibody directed against
glycosylated aDG (1). The number of IIH6-positive cells
strongly increased on transfection with wild-type B3GNT1
when compared with transfection with an empty vector. Trans-
fection with single mutants and the double mutant did not
cause an increase of IIH6-positive cells. Normalization of
the results as percentage of IIH6-positive cells in relation to
the empty vector control showed a statistically significant dif-
ference in aDG glycosylation between wild-type and mutant
constructs (Fig. 4; P ¼ 0.042). These results indicate that the
identified mutations impair the glycosyltransferase function
of B3GNT1.
Morpholino knockdown of zebrafish b3gnt1
To evaluate the phenotypic consequences of loss of function of
B3GNT1 in vivo, we used zebrafish embryos as a model for
the dystroglycanopathies (21). The zebrafish ortholog,
B3gnt1, shows 67% similarity to the human B3GNT1
protein sequence, including conservation of the two amino
acid residues mutated in the family affected by WWS:
Asn390 and Ala406 (Supplementary Material, Fig. S1).
Figure 1. Schematic representation of B3GNT1 chromosomal position, protein structure and localization of mutations. (A) Ideogram of chromosome 11 showing
the localization of the SNPs flanking the shared homozygous region in the patients. (B) Zoom-in of the 5.2 Mb homozygous region. (C) Gene structure of
B3GNT1 showing the 5′ UTR, two coding exons separated by the intron and the 3′ UTR. (D) Protein structure of B3GNT1 showing the topological
domains, the conserved glycosyltransferase domain and the position of the missense mutations M1 (p.N390D) and M2 (p.A406V). (E) Pedigree of
family WWS-31. Individuals that were available for study are identified by their lab number. The mutation status is indicated below each individual
(+, present, 2, absent, NA, not available).
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RT-PCR analysis showed that b3gnt1 is expressed in wild-
type embryos throughout the first five days of development
(Fig. 5A). To knockdown b3gnt1, we injected zebrafish
embryos with a morpholino designed to disrupt splicing of
the only intron in the b3gnt1 gene (Fig. 1C). We observed a
great reduction in the expression of the full-length transcript
and the appearance of aberrantly spliced transcripts by
RT-PCR (Fig. 5B), using complementary DNA (cDNA)
extracted from 48 h post fertilization (hpf) morphant embryos.
To assess the effect of loss of function of B3gnt1 on glyco-
sylation of aDG, we extracted cell surface proteins from
48 hpf uninjected (positive control), b3gnt1 morpholino-
treated and dag1 morpholino-treated (negative control)
embryos. We tested the protein extracts for the presence of
laminin-binding glyco-epitopes by western blot, using the
IIH6 antibody (Fig. 5C). Little or no glycosylated aDG was
observed in extracts from b3gnt1 morphants compared to
wild-type. These results demonstrate that loss of function of
B3gnt1 results in hypoglycosylation (Fig. 5C) and verifies
the efficacy of the morpholino.
To investigate the effect of b3gnt1 morpholino knockdown
on the muscle fibre structure and organization, we stained
48 hpf morphant and control embryos with phalloidin, which
labels filamentous actin (F-actin) and an antibody against
bDG to label myotendinous junctions (MTJs). Muscle fibre or-
ganization and structure were disrupted in morphant embryos
(Fig. 5D), including muscle fibre detachment and discontinu-
ous MTJs, with elongated muscle fibres spanning the myo-
septa. Sarcolemma integrity was evaluated by injection of
Evan’s blue dye (EBD), which only penetrates the cell when
the membrane is compromised (Fig. 5E). Accumulation of
EBD was observed in the muscle lesions, indicating muscle
degeneration with a loss of sarcolemma integrity in b3gnt1
morphant embryos.
Taken together, these results demonstrate that the missense
mutations in B3GNT1 in this WWS family significantly impair
its function in vitro as well as in vivo in zebrafish, showing a
muscle phenotype comparable with dystroglycanopathy.
DISCUSSION
Dystroglycanopathies are caused by mutations in (putative)
glycosyltransferases and sugar donors that result in aberrant
glycosylation of aDG. Identification of all genes involved is
essential for understanding the pathology in this group of dis-
orders with abnormal glycosylation of the aDG glycan. In this
study, we identified two missense mutations in B3GNT1 in a
family affected with WWS and showed that these mutations
are causative for the disease. First, the mutations reside in
the conserved glycosyltransferase domain, show complete seg-
regation with the disease in the index family and are absent in
Figure 2. (A–D) MRI at 4 months of age. Sagittal T2W image (A) reveals
hydrocephalus, a hypoplastic ‘Z’-shaped brainstem (arrow) and a hypoplastic,
dysplastic vermis. Coronal T1W image (B) demonstrates absence of the septal
leaflets, vertical hippocampi and fusion of the forniceal columns in the midline
(arrow). Axial T2W image (C) shows focal cobblestone lissencephaly of the
occipital cortex (arrow). The subjacent white matter is abnormally increased
in signal intensity. A shunt is present in the posterior horn of the right
lateral ventricle. In addition to ventriculomegaly and focal cobblestone lissen-
cephaly, coronal T2W image (D) reveals cysts (arrow) within the dysplastic
cerebellum. (E) Patient (P) and control (C) muscle homogenates were used
for a laminin overlay assay (LO). b-Dystroglycan (b-DG) staining was used
as loading control.
Figure 3. Cellular localization of wild-type and mutant B3GNT1. Wild-type
and mutant variants of EGFP-tagged B3GNT1 (green) colocalize with the
Golgi marker Giantin (red). Scale bar represents 10 mm.
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control cohorts. Second, B3GNT1 overexpression in human
PC3 cells results in a significant increase in aDG glycosyla-
tion, whereas overexpression of singly or doubly mutated
B3GNT1 is comparable with the negative control. This demon-
strates the involvement of B3GNT1 in aDG glycosylation and
the pathogenicity of the missense mutations. Third, morpho-
lino knockdown of the zebrafish ortholog b3gnt1 results in
phenotypic features that are reminiscent of WWS, with
muscle structure disorganization being the most prominent
finding. Taken together, these results indicate that B3GNT1
is required for the interaction between aDG and laminin, as
impaired B3GNT1 function leads to diminished glycosylation
and subsequent disruption of ligand binding, leading to pheno-
typic WWS features. Previous genetic analyses in patients
with mild-end dystroglycanopathy phenotypes have not
revealed B3GNT1 mutations (32). Furthermore, we have iden-
tified only one family in our cohort of WWS patients, suggest-
ing that it is a rare cause of dystroglycanopathies. One
hypothesis is that more severe mutations might cause embry-
onic lethality and have hitherto remained undetected.
The exact function of B3GNT1 in aDG O-mannosylation is
still unknown. B3GNT1 is expressed in tissues typically
affected in dystroglycanopathies, including skeletal muscle
and brain (33). Previous studies in a prostate cancer cell line
(28) indicated a role of B3GNT1 in the synthesis of the
laminin-binding glycan. B3GNT1 was originally characterized
as an enzyme involved in the formation of poly-N-acetyllacto-
samine glycans by adding N-acetylglucosamine residues to
N-acetyllactosamines attached to N-glycans (33). It has been
proposed that B3GNT1 forms a complex with LARGE and
that terminal N-acetylglucosamine residues are targets for
LARGE glycosyltransferase activity (31,34). One possibility
is that B3GNT1 adds a terminal N-acetylglucosamine residue
to the phosphodiester-linked glycan that acts as an acceptor
for LARGE activity. A recent study has shown that LARGE
transfers both xylose and glucuronic acid residues to the
unknown ligand-binding glycan (28), perhaps using the
N-acetylglucosamine residue transferred by B3GNT1 as initi-
ating sugar. It is not yet known how these xylose and glucur-
onic acid structures contribute to ligand binding. Together
with previous studies, our data suggest that at least three
N-acetylglucosaminyl transferases with different specificities
are required for synthesis of the ligand-binding glycan on
aDG. POMGnT1 is responsible for addition of an
N-acetylglucosamine residue in b-1,2 linkage to the first
mannose residue. However, the N-acetylglucosamine residue
in the phosphodiester-linked O-mannose trisaccharide was
proposed in the b-1,4 linkage, while B3GNT1 is supposed
to add an N-acetylglucosamine residue in the b-1,3 linkage,
likely in the post-phosphoryl glycan (15,33). Altogether, the
synthesis of the laminin-binding glycan on aDG still
remains unclear, necessitating further mechanistic studies to
position uncharacterized proteins as FKRP, FKTN, GTDC2
and ISPD in the pathway (15,21).
In conclusion, we have detected two pathogenic missense
mutations in B3GNT1 which result in impaired glycosylation
of aDG, giving rise to WWS. Our genetic and functional
data provide evidence that B3GNT1 is a novel causative
gene for the dystroglycanopathies and recommend its inclu-
sion in the diagnostic workup of patients.
MATERIALS AND METHODS
Clinical report
The index family (WWS-31) is a non-consanguineous family
of East Indian descent with four affected children and three
unaffected siblings (Fig. 1E). The mother had a history of ges-
tational diabetes. The remainder of the family history is non-
contributory for additional risk factors. The couple’s first preg-
nancy, when the parents were 25 years old, resulted in a
daughter who is well.
The second pregnancy was complicated with fetal ultra-
sound findings, at 22 weeks of gestation, of hydrocephalus
with the lateral ventricles measuring 24 mm each and the
third ventricle measuring 5 mm. The cerebellum and brain-
stem were hypoplastic. The pregnancy was terminated at
24.9 weeks gestation and the autopsy showed diffuse and
severe leptomeningeal neuroepithelial heterotopia, maximal
over the convexity of the cerebral hemispheres and ventral
brainstem. There was obliteration of the subarachnoid space
and diffuse communicating hydrocephalus. There was severe
dysplasia/hypoplasia of the cerebellar hemisphere and
Figure 4. Flow cytometry analysis of transfected PC3 cells. PC3 cells trans-
fected with an empty vector are used as control (A). In B3GNT1 WT
transfected PC3 cells (B) the percentage of IIH6-positive cells is significantly
higher than in PC3 cells transfected with an empty vector (A, F). The percen-
tages of IIH6-positive cells in B3GNT1 M1 (C), B3GNT1 M2 (D) and
B3GNT1 M1M2 (E) transfected PC3 cells are comparable with the percentage
of the PC3 cells transfected with the empty vector (A, summary in F), indicat-
ing that glycosylation is affected. (F) Bar chart showing the relative amount of
IIH6-positive cells, taking the empty vector control as standard
(n ¼ 3, ∗P , 0.05, one sample T-test). Error bars show the standard deviation.
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vermis and ventral brainstem hypoplasia, maximal at the basis
pontis. The karyotype was normal (46, XX).
The third pregnancy was complicated with cerebral ventri-
culomegaly involving the lateral and third ventricles with a
very thin and smooth cortex at 23 weeks gestation. The cere-
bellum was hypoplastic and the cisterna magna was enlarged.
There was multicystic dysplastic left kidney and very few tiny
cysts appeared in the right kidney. The karyotype was normal
(46, XY). The couple was counselled and decided to termin-
ate the pregnancy. The autopsy showed a male fetus with a
cystic dysplastic left kidney with a thread-like ureter, testicu-
lar hypoplasia with decreased number and marked size vari-
ation of seminiferous tubules, 12 ribs on the right and 11
on the left and X-ray finding of ‘beaten silver’ frontal and par-
ietal skull bones. Neuropathological investigation showed lis-
sencephaly type II with cortical dysplasia, severe wavy island
architecture and extensive glio-neuroepithelial leptomeningeal
heterotopia with obliteration of the subarachnoid space. There
was severe communicating hydrocephalus. The cerebellum
showed severe cortical dysplasia/hypoplasia with inferior
vermian defect. There was hypoplasia of the pyramids at
the level of the medulla and the inferior olives had a
C-shaped dysplasia. There was hydromyelia. The eyes
showed no anterior segmental abnormalities, focal abnormal-
ities involving the retinae of both eyes including the disorga-
nized neuronal layer with irregular nests of neurons in the
nerve fibre layer, some of which appeared to break through
the inner limiting membrane. There were no abnormalities
of the extraocular muscles. The findings were consistent
with retinal dysplasia.
The fourth pregnancy resulted in a son who is well.
The fifth pregnancy resulted in a fetus with WWS. The fetal
ultrasound at 17.6 weeks gestation showed a slight ‘lemon’-
shaped head with bilateral ventriculomegaly measuring
14 mm, a small cerebellum and agenesis of the corpus callo-
sum and inferior vermis. A repeat fetal ultrasound at 21.5
weeks gestation showed hydrocephalus with the lateral ventri-
cles measuring 17 mm. The cerebellum was slightly small and
there was partial vermian dysgenesis. The couple was coun-
selled and decided to terminate the pregnancy. The autopsy
showed a female fetus with findings consistent with WWS in-
cluding extensive glio-neuroepithelial leptomeningeal hetero-
topia with obliteration of the subarachnoid space. There was
severe communicating hydrocephalus. There was lissence-
phaly, absent pyramidal tract and agenesis of the corpus callo-
sum. The cerebellum showed severe cortical dysplasia/
hypoplasia and aplasia of the vermis.
The couple’s sixth pregnancy resulted in a son, who was
diagnosed prenatally with WWS. The couple was counselled
and decided to continue the pregnancy. The baby was born
at term via Cesarean section due to severe cerebral ventricu-
lomegaly. He presented with hydrocephalus, Dandy–Walker
malformation, retinal dysplasia, severe hypotonia and intract-
able seizures. His CK level was very high (3180 units/l) and
the MRI (Fig. 2) showed ventricular enlargement, diffuse
widening of the gyri and disorganization of the cortical
sulci with areas of cobblestone lissencephaly along the pos-
terior aspects of the occipital lobes and temporal lobes.
There was white matter abnormality in association with
these findings. The brain stem was severely abnormal with
wasting of the pons and medulla. The cerebellum was also
extremely dysgenetic with cysts, heterotopia and disarray
of cortical migration. There was absence of the septum pel-
lucidum and fusion of the forniceal columns in the midline.
The globes were apparently intact with thinning of the pos-
terior sclera and retina, consistent with retinal dysplasia. He
had a ventriculoperitoneal shunt inserted and died at 2 years
of age.
Figure 5. Knockdown of zebrafish b3gnt1 causes muscle defects and reduced glycosylation of aDG. (A and B) RT-PCR results showing that b3gnt1 is expressed
throughout zebrafish embryonic development (A) but greatly reduced in 48 hpf embryos treated with 6 ng or 9 ng of b3gnt1 morpholino (2c, two-cell stage; Shd,
shield stage; d, days post fertilization) (B), compared with b-actin loading control; arrow indicates aberrantly spliced b3gnt1 transcripts. (C) Western blot using
IIH6 antibody to detect the aDG glycosylation state (Glyco. aDag1) in 48 hpf wild-type (wt), b3gnt1 morphant (bMO) or dag1 morphant (dMO) embryos.
Knockdown of b3gnt1 causes hypoglycosylation of aDG compared with wild-type. Ponceau staining (PonS) loading control shown below. (D) Fluorescent con-
focal microscopy images of 48 hpf wild-type (top) and b3gnt1 morphant (bottom) embryos stained with phalloidin (green), and the corresponding DIC images.
Loss of function of b3gnt1 results in disrupted MTJs as indicated by bDG immunoreactivity (red) and muscle fibres spanning multiple segments. (E) Compro-
mised sarcolemmal integrity precedes fibre detachment in b3gnt1 morpholino-treated embryos. Fluorescent confocal microscopy image of a 48 hpf embryo,
previously injected with b3gnt1 splice-blocking morpholino, treated with EBD (top panel) to highlight muscle fibres with disrupted sarcolemma (arrows).
The corresponding DIC image is shown in the middle panel. Representative images of identified muscle lesions from three independent experiments; scale
bar represents 50 mm.
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The couple’s seventh pregnancy resulted in a daughter who
is well.
Patient cohort
A cohort of 55 families with one or more individuals affected
with WWS or MEB were included in this study. Informed
consent was obtained from all participants. The study was
approved by the ethical board of the Radboud University Nij-
megen Medical Centre, CMO Regio Arnhem-Nijmegen Ap-
proval 2011/155.
Homozygosity mapping
Genotyping analysis of genomic DNA was performed using
the Affymetrix GeneChip Human Mapping 10 K 2.0 Array
or 250 K NspI Array. All SNP array experiments were per-
formed and analysed according to the manufacturer’s instruc-
tions (Affymetrix, Santa Clara, CA, USA). Homozygosity
mapping was performed using an in-house algorithm (J.v.R.,
unpublished data) for analysis of the genotype files generated
by the Affymetrix GTC software. The number of contiguous
homozygous SNPs required for significance in relation to the
degree of consanguinity for each individual was calculated
using an algorithm adapted from a previous study (35).
Regions of excess homozygosity were identified in affected
individuals and compared with haplotypes of unaffected
family members where available.
B3GNT1 mutation analysis
Sequencing of the two coding exons of B3GNT1 (NCBI Ref-
erence Sequence NM_006876.2) was performed using the ABI
PRISM BigDye Terminator Cycle Sequencing V2.0 Ready
Reaction kit and analysed with the ABI PRISM 3730 DNA
analyzer (Applied Biosystems, Foster City, CA, USA).
Primer sequences and PCR conditions are available upon
request.
Molecular cloning and site-directed mutagenesis
Full-length human B3GNT1 mRNA was obtained from
IMAGE cDNA clone 2 988 041 (Source BioScience). The
wild-type human-coding sequences were cloned into the
Gateway pDONRTM201 vector (Invitrogen). Site-directed mu-
tagenesis using the QuikChangeTM Site-Directed Mutagenesis
kit (Stratagene) was carried out to introduce the mutations into
the constructs. The presence of the mutations was verified by
Sanger sequencing. The human c.1168A.G mutation is re-
ferred to as mutation 1 (M1). The c.1217C.T mutation is re-
ferred to as mutation 2 (M2). Both single (M1 or M2) and
double mutant (M1M2) constructs were designed. Wild-type
and mutant sequences were subsequently cloned into pCS2+
based expression vectors that were used for mRNA synthesis
and transfection.
Accession number
To clone full open reading frame (ORF) zebrafish b3gnt1, we
carried out RT-PCR using cDNA from 48 hpf embryos with
forward and reverse primers, 5′-TCTTTTTTTTGCTATCCAAAC-3′
and 5′-GCATTCATGAGTGTCTCCTTACA-3′. The full ORF
zebrafish b3gnt1 cDNA has been submitted to GenBank (Acces-
sion number: KC136354).
Western blotting
For human muscle tissues, proteins were extracted from
paraffin-embedded muscle as described (36). Protein samples
were used for western blotting followed by a laminin
overlay assay and b-dystroglycan staining as described
(1,24). Microsome preparation and western blotting using zeb-
rafish embryos were carried out as previously described (21).
The primary antibody used in this study was glycosylated
a-dystroglycan IIH6 (Millipore, 1:2000).
Cell culture and transfection
Prostate cancer cells (PC3) (a gift from Gerald Verhaegh of
the Department of Urology, Radboud University Nijmegen
Medical Centre) were cultured in RPMI 1690 medium
(Gibco) supplemented with 10% fetal bovine serum (PAA).
Cells were transfected using FuGENEw 6 (Roche) according
to manufacturer’s instructions. The ratio of transfection
reagents (ml) to DNA (mg) used was 6:1. Three days after
transfection, the cells were used for immunocytochemistry
or flow cytometry analysis.
Immunocytochemistry
Transfected and untransfected cells were cultured on glass
cover slips. The cells were briefly washed using phosphate
buffered saline (PBS), fixed in 3.7% formaldehyde in PBS at
room temperature for 10 min, permeabilized using 0.4%
Triton X-100 in 3% BSA/PBS at 48C for 10 min, blocked
with 3% BSA/PBS at room temperature for 30 min and subse-
quently incubated with Giantin antibody (Covance) diluted
1:400 in 3% BSA/PBS at 48C for 1 hour. Following primary
antibody incubation, the cells were briefly washed using
PBS and subsequently incubated with Alexa Fluorw 555
Donkey Anti-Rabbit IgG (Molecular Probes) diluted 1:500
in 3% BSA/PBS at 48C for one and a half hour. Cover slips
were embedded in fluorescence mounting medium (DAKO).
The cells were analysed using a Zeiss Axio Imager Z1 fluor-
escence microscope (Carl Zeiss).
Flow cytometry analysis
Cells were washed using PBS and subsequently scraped in
cold PBS. The cells were blocked using 20% goat serum in
1% BSA/PBS on ice for 20 min. The cells were incubated
with IIH6 antibody (Millipore) 1:25 diluted in 1% BSA/PBS
on ice overnight. The cells were washed and subsequently
incubated with Alexa Fluorw 647 Goat Anti-Mouse IgG (Mo-
lecular Probes) 1:200 diluted in 1% BSA/PBS on ice for 2
hours. The fluorescent signal of secondary antibody was mea-
sured using a CyAn flow cytometer (Beckman-Coulter) with
642 nm laser. A total of 75 000 cells were analysed per experi-
ment. Data were analysed using Summit 4.3 software. The
percentage of IIH6-positive cells transfected with wild-type
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and mutant B3GNT1 constructs was normalized against the
percentage of IIH6-positive cells transfected with the empty
vector (Fig. 4F). Statistical significance was determined
using one-sample t-test (n ¼ 3). A P-value of ,0.05 was con-
sidered statistically significant.
Morpholino and EBD injections in zebrafish
Antisense morpholino oligonucleotides (MOs) were obtained
from GeneTools. dag1 MO has been described (37). b3gnt1
MO (5′-CCTATTCTCCATGTGCTCACCTGGC-3′) was
designed to target the b3gnt1 exon–intron splice site. All
MOs were injected into the yolk flow at one-cell stage using a
specified dose in the figure legend. As described (38), 0.1%
EBD (Sigma) was injected into zebrafish blood circulation at
48 hpf. MO or EBD-injected embryos were fixed using 4%
PFA for immunohistochemistry or analysed live under confocal
and differential interference contrast (DIC) microscopy.
Zebrafish immunohistochemistry
Immunostaining of fixed zebrafish embryos was performed as
described (21). Alexa Fluor-conjugated phalloidin (Molecular
Probes; 1:100 dilution) and primary antibody anti-b-Dag1
(Novocastra, 1:50) were used. Alexa Fluorw 488 or 594 con-
jugated anti-mouse IgG (Molecular Probes; 1:250 dilution)
were used as a secondary antibody.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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